promoted the expression of glial fibrillary acidic protein

Everolimus was analyzed in an orthotopic rat grade Two chondrosar coma model in macroscopic and adjuvant cycle each reaching the same conclusion. Being a single agent, the mTOR inhibitor everolimus did not cause tumor regression but caused an important inhibition of tumor growth. Both size and tumor growth rate were small AZD 3839 within the everolimus treated groups than in other groups, as observed in other tumor models, Doxorubicin was lazy as one agent, when combined with everolimus, an antagonistic effect was actually observed in the, combination group set alongside the everolimus treated group. In comparison with doxorubicin alone, the combination treatment showed however a heightened therapeutic efficiency. The same effect was recently reported, although these data are strongly contrasting with those observed in breast cancer types with paclitaxel and prostate cancer with doxoru bicin. In Lymphatic system human cervical carcinoma xenograft models the addition of everolimus to doxorubicin showed an anti-tumor effect that has been not significantly distinctive from doxorubicin monotherapy, The mechanisms underlying this lack of synergism between the two drugs are uncertain. One of many negative effects of doxorubicin treatment is the induction of reactive oxygen species which often can trigger the RafMEKERK and PI3KPTENAktmTOR walkways, This service of the mTORAkt pathway induced by doxorubicin is reflected by small increase in Akt phosphorylation in the doxorubicin treated group of our research. While in the chondrosarcoma model the activity of the mTOR pathway in response to the different treatments was monitored by following activation levels of 4EBP1, S6K as possible surrogate markers of tumor response.